OMRIX Biopharmaceuticals, Inc. ("OMRIX" or "The
Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company
that develops and markets biosurgical and passive immunotherapy
products, will announce financial results for the second quarter ended
June 30, 2006 after the close of U.S. financial markets on Tuesday,
August 8, 2006. An accompanying conference call to discuss the results
will be held the same day at 5:00 p.m. EDT; 2:00 p.m. PDT.
To access the live telephonic broadcast, U.S. callers should dial
(800) 819-9193; international callers may dial (913) 981-4911. A live
audio webcast of the call will be available at the Company's website
at www.omrix.com. Participants are urged to log on to the website 15
minutes prior to the scheduled start time to download and install any
necessary software.
An audio replay of the conference call will be available from 8:00
p.m. EDT on Tuesday, August 8, 2006 through 11:59 p.m. EDT on Tuesday,
August 15th by dialing (888) 203-1112 from the U.S. or (719) 457-0820
when calling internationally, and entering confirmation code 4747620.
The audio webcast will be available on the company's website,
www.omrix.com, for 30 days. The financial results press release will
also be accessible on the company's website at www.omrix.com.
About OMRIX Biopharmaceuticals, Inc.
OMRIX, a commercial-stage biopharmaceutical company, develops and
markets innovative biosurgical and passive immunotherapy products,
utilizing its proprietary protein purification technology and
manufacturing know-how. As part of its business strategy, OMRIX
commercializes certain of its biosurgical products through
collaborations with companies whose marketing and sales expertise are
a complement to OMRIX's own areas of specialty. OMRIX's novel and
easy-to-use biological-device convergence products address unmet
medical needs. For more information, please visit: www.omrix.com.
Safe Harbor Statement
This press release contains forward-looking statements.
Forward-looking statements provide the company's current expectations
or forecasts of future events. Forward-looking statements include
statements about the company's expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking
statements, but the absence of these words does not necessarily mean
that a statement is not forward-looking.
Forward-looking statements are subject to known and unknown risks
and uncertainties and are based on potentially inaccurate assumptions
that could cause actual results to differ materially from those
expected or implied by the forward-looking statements. The company's
actual results could differ materially from those anticipated in
forward-looking statements for many reasons, including the factors
described in the sections entitled "Risk factors" and "Management's
discussion and analysis of financial condition and results of
operations" in the company's Prospectus as filed with the Securities
and Exchange Commission on April 21, 2006. Accordingly, you should not
unduly rely on these forward-looking statements, which speak only as
of the date of this press release.
Unless required by law, the company undertakes no obligation to
publicly revise any forward-looking statement to reflect circumstances
or events after the date of this press release or to reflect the
occurrence of unanticipated events. You should, however, review the
factors and risks we describe in the reports the company will file
from time to time with the Securities and Exchange Commission after
the date of this press release.
